Latest Breaking News On - Progressive multiple myeloma after - Page 1 : comparemela.com

Longer term follow-up data will be presented from the pivotal CARTITUDE-1 study in patients with relapsed or refractory multiple myeloma, which supported the recent U.S. FDA approval of CARVYKTI

United statesNew jerseyCiltacabtagene autoleucelHemophagocytic lymphohistiocytosisJoanne choiYing huangTina carterJanssen biotech incExchange commission onAmerican society of clinical oncologyEuropean hematology associationDrug administrationChinese centerLegend biotech corporationCorporate communicationsEuropean union